The CHU de Toulouse is a premier French university hospital center and the largest healthcare institution in the Occitanie region. It operates as a public entity with a triple mission: providing specialized healthcare, training healthcare professionals, and conducting medical research in partnership with the University Toulouse III-Paul Sabatier and national research bodies like INSERM and CNRS.
The institution is organized into multiple sites, including the major hospital centers of Purpan and Rangueil-Larrey. It is a national leader in several medical fields, including oncology, rare diseases, and intensive care, and frequently ranks among the top hospitals in France for its clinical activity and research output.
CLASSIFICATION
Company Type:MedTech
Therapeutic Areas:
Industry:Medical Devices
Sub-Industry:Academic Medical Center / Hospital
SIZE & FINANCIALS
Employees:10000+
Ownership:government
Status:operating
PIPELINE
Stage:Discovery
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:University Toulouse III-Paul Sabatier (Academic partner), INSERM (Research partner), CNRS (Research partner), Institut Universitaire du Cancer de Toulouse (IUCT) (Oncology partnership)
COMPETITION
Position:Leader
LEADERSHIP
Key Executives:
Jean-François Lefebvre - Directeur Général
Pr. Fatemeh Nourhashemi - Président de la Commission Médicale d'Etablissement
LINKS
Website:chu-toulouse.fr
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Centre Hospitalier Universitaire (CHU) de Toulouse and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Centre Hospitalier Universitaire (CHU) de Toulouse. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.